pb
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2022 (NCT05190744)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06608901 | Phase 2 | Dec 9, 2024 | Regeneron |
| NCT05190744 | Phase 2 | Sep 1, 2022 | Mayo Clinic, University of Montreal |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Regeneron | For profit | 1 | 1 | 1 | 2024 |
| University of Montreal | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1